Cover Image
市場調查報告書

脂肪酸醯胺水解酵素 (FAAH):開發平台分析

Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 359837
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
脂肪酸醯胺水解酵素 (FAAH):開發平台分析 Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 58 Pages
簡介

本報告提供以脂肪酸醯胺水解酵素 (FAAH) 為標的的藥物之適應症,開發階段,作用機制,給藥途徑及各分子類型分析,提供您藥物的藥理作用相關記述,迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

脂肪酸醯胺水解酵素概要

治療藥的開發

脂肪酸醯胺水解酵素:開發中的產品 - 各開發階段

脂肪酸醯胺水解酵素:開發中的產品 - 各治療範圍

脂肪酸醯胺水解酵素:開發中的產品 - 各適應症

脂肪酸醯胺水解酵素:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

脂肪酸醯胺水解酵素:企業開發中的產品

脂肪酸醯胺水解酵素:大學/機關開發中的產品

脂肪酸醯胺水解酵素:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

脂肪酸醯胺水解酵素的治療藥開發企業

  • Advinus Therapeutics Ltd.
  • Johnson & Johnson
  • MAKScientific, LLC
  • Midatech Pharma US Inc.
  • Sigma-Tau S.p.A.
  • 武田藥品工業
  • Zynerba Pharmaceuticals, Inc.

藥物簡介

脂肪酸醯胺水解酵素:暫停中的計劃

脂肪酸醯胺水解酵素:開發中止的產品

脂肪酸醯胺水解酵素:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0555TDB

Summary

Global Markets Direct's, 'Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Pipeline Review, H2 2016', provides in depth analysis on Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted pipeline therapeutics.

The report provides comprehensive information on the Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99)
  • The report reviews Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Overview
  • Therapeutics Development
    • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Products under Development by Stage of Development
    • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Products under Development by Therapy Area
    • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Products under Development by Indication
  • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Products under Development by Companies
  • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Products under Development by Universities/Institutes
  • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Companies Involved in Therapeutics Development
    • Advinus Therapeutics Ltd
    • Johnson & Johnson
    • MAKScientific, LLC
    • Midatech Pharma US Inc.
    • Takeda Pharmaceutical Company Limited
    • Zynerba Pharmaceuticals, Inc.
  • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Drug Profiles
    • AM-3506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-5206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPI-940 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-40413269 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KRN-5500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit FAAH for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit COX and FAAH for Oncology, Immunology and CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-694 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZYN-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Dormant Projects
  • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Discontinued Products
  • Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) - Featured News & Press Releases
    • Sep 06, 2016: Zynerba Pharmaceuticals Launches Phase 2 Clinical Trial of ZYN002 CBD Gel for Treatment of Osteoarthritis
    • Aug 01, 2016: Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures
    • Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures
    • Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid
    • Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome
    • Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial
    • Oct 20, 2015: Zynerba Pharmaceuticals Initiates Phase 1 Clinical Trial for ZYN002 CBD Gel
    • Jun 16, 2014: DARA BioSciences' KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma
    • Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA
    • Nov 29, 2012: Dara BioSciences Submits Orphan Drug Application For KRN5500 To FDA
    • May 09, 2012: Dara To Advance Development Of KRN5500 For Treatment Of Cancer And Neuropathic Pain
    • Oct 10, 2011: DARA BioSciences Announces KRN5500 Demonstrated Significant Decrease In Intensity Of Neuropathic Pain In Patients With Cancer
    • Sep 15, 2011: DARA BioSciences To Present Positive Results Of KRN5500 Phase II Study At 5th Annual Therapeutics Summit
    • Aug 18, 2011: DARA BioSciences Receives Fast Track Designation From FDA For KRN5500 For Treatment Of Chemotherapy-Induced Neuropathic Pain In Patients With Cancer
    • Jun 01, 2011: Infinity To Provide Update On IPI-940
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Advinus Therapeutics Ltd, H2 2016
  • Pipeline by Johnson & Johnson, H2 2016
  • Pipeline by MAKScientific, LLC, H2 2016
  • Pipeline by Midatech Pharma US Inc., H2 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top